Lilly starts late-stage study of coronavirus drug in nursing homes
FDA commissioner: Overseeing more than 140 coronavirus treatment clinical trials
FDA Commissioner Dr. Stephen Hahn discusses combatting the coronavirus through public health guidelines and the development of therapeutics.
(Reuters) – U.S. drugmaker Eli Lilly & Co said on Monday it is beginning a late-stage trial to study whether one of its experimental COVID-19 antibody treatments can prevent the virus’ spread in residents and staff in U.S. nursing homes.
Continue Reading Below
The phase 3 trial will test LY-CoV555, a treatment developed in partnership with Canadian biotech AbCellera, is expected to enroll up to 2,400 participants who live or work at a facility that have had a recently diagnosed case of COVID-19.
J&J BEGINS CLINICAL TRIAL OF SINGLE-DOSE CORONAVIRUS VACCINE
“COVID-19 has had a devastating impact on nursing home residents,” Lilly’s chief scientific officer Daniel Skovronsky said in a statement. “We’re working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals.”
Lilly is already testing the drug in hospitals to study whether it can work as a treatment in patients who have the disease. This trial will test whether it works prophylactically.